Biotech Values

[dav1234]

4:10PM Xenoport misses by $0.11, misses on revs (XNPT) 6.05 +0.04 : Reports Q3 (Sep) loss of $0.55 per share, $0.11 worse than the Capital IQ Consensus Estimate of ($0.44); revenues were unchanged from the year-ago period at $0.4 mln. GlaxoSmithKline (GSK), XenoPort's collaborator for Horizant(TM) (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults in the United States, started promoting Horizant in July 2011. GSK filed a supplemental new drug application (sNDA) under Section 505(b)(2) for Horizant in the management of post-herpetic neuralgia (PHN). XenoPort completed enrollment of a Phase 2b trial of XP21279 as a potential treatment of patients with Parkinson's disease and expects top-line results by the end of 2011.